aspirin has been researched along with Squamous Cell Carcinoma of Head and Neck in 4 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Squamous Cell Carcinoma of Head and Neck: The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We identified 10 770 patients with HNSCC during a median follow-up of 3." | 1.72 | Low-dose aspirin use and mortality risk in patients with head and neck cancer: A nationwide cohort study of 10 770 patients. ( Carlander, AF; de la Cour, CD; Dehlendorff, C; Friis, S; Garset-Zamani, M; Grønhøj, C; Kjaer, SK; von Buchwald, C, 2022) |
| "Aspirin or NSAID use was considered positive if the patients were receiving aspirin or NSAID medication from HNSCC diagnosis to at least 1 year after treatment initiation." | 1.48 | Aspirin use and head and neck cancer survival: an observational study of 11,623 person-years follow-up. ( Choi, SH; Kim, SA; Kim, SB; Kim, SY; Nam, SY; Roh, JL, 2018) |
| "The co-occurrence of HNSCC and secondary primary cancer (SPC) and the chemopreventive effect of aspirin on certain malignancies had been reported." | 1.48 | Aspirin associated with risk reduction of secondary primary cancer for patients with head and neck cancer: A population-based analysis. ( Chou, YS; Huang, SF; Kuo, LT; Lin, YS; Muo, CH; Su, CT; Su, FH; Sung, FC; Yeh, CC, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| de la Cour, CD | 1 |
| von Buchwald, C | 1 |
| Dehlendorff, C | 1 |
| Garset-Zamani, M | 1 |
| Grønhøj, C | 1 |
| Carlander, AF | 1 |
| Friis, S | 1 |
| Kjaer, SK | 1 |
| Iovoli, AJ | 1 |
| Hermann, GM | 1 |
| Ma, SJ | 1 |
| Platek, AJ | 1 |
| Farrugia, MK | 1 |
| Yau, E | 1 |
| Wooten, KE | 1 |
| Arshad, H | 1 |
| Gupta, V | 1 |
| Kuriakose, MA | 1 |
| Hicks, WL | 1 |
| Singh, AK | 1 |
| Kim, SA | 1 |
| Roh, JL | 1 |
| Kim, SB | 1 |
| Choi, SH | 1 |
| Nam, SY | 1 |
| Kim, SY | 1 |
| Lin, YS | 1 |
| Yeh, CC | 1 |
| Huang, SF | 1 |
| Chou, YS | 1 |
| Kuo, LT | 1 |
| Sung, FC | 1 |
| Muo, CH | 1 |
| Su, CT | 1 |
| Su, FH | 1 |
4 other studies available for aspirin and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Low-dose aspirin use and mortality risk in patients with head and neck cancer: A nationwide cohort study of 10 770 patients.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cohort Studies; Female; Head and Neck Neoplasms; Humans; Ma | 2022 |
Association of Nonsteroidal Anti-inflammatory Drug Use With Survival in Patients With Squamous Cell Carcinoma of the Head and Neck Treated With Chemoradiation Therapy.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemoradiotherapy; Female; Head and Neck Neo | 2020 |
Aspirin use and head and neck cancer survival: an observational study of 11,623 person-years follow-up.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Squamou | 2018 |
Aspirin associated with risk reduction of secondary primary cancer for patients with head and neck cancer: A population-based analysis.
Topics: Adult; Aged; Aspirin; Female; Humans; Incidence; Male; Middle Aged; Neoplasms, Second Primary; Regis | 2018 |